...
首页> 外文期刊>Brain: A journal of neurology >Exome sequencing reveals a novel Moroccan founder mutation in SLC19A3 as a new cause of early-childhood fatal Leigh syndrome
【24h】

Exome sequencing reveals a novel Moroccan founder mutation in SLC19A3 as a new cause of early-childhood fatal Leigh syndrome

机译:外显子组测序揭示SLC19A3中新的摩洛哥奠基人突变是导致儿童早期致命Leigh综合征的新原因

获取原文
获取原文并翻译 | 示例
           

摘要

Leigh syndrome is an early onset, often fatal progressive neurodegenerative disorder caused by mutations in the mitochondrial or nuclear DNA. Until now, mutations in more than 35 genes have been reported to cause Leigh syndrome, indicating an extreme genetic heterogeneity for this disorder, but still only explaining part of the cases. The possibility of whole exome sequencing enables not only mutation detection in known candidate genes, but also the identification of new genes associated with Leigh syndrome in small families and isolated cases. Exome sequencing was combined with homozygosity mapping to identify the genetic defect in a Moroccan family with fatal Leigh syndrome in early childhood and specific magnetic resonance imaging abnormalities in the brain. We detected a homozygous nonsense mutation (c.20C>A; p.Ser7Ter) in the thiamine transporter SLC19A3. In vivo overexpression of wild-type SLC19A3 showed an increased thiamine uptake, whereas overexpression of mutant SLC19A3 did not, confirming that the mutation results in an absent or non-functional protein. Seventeen additional patients with Leigh syndrome were screened for mutations in SLC19A3 using conventional Sanger sequencing. Two unrelated patients, both from Moroccan origin and one from consanguineous parents, were homozygous for the same p.Ser7Ter mutation. One of these patients showed the same MRI abnormalities as the patients from the first family. Strikingly, patients receiving thiamine had an improved life-expectancy. One patient in the third family deteriorated upon interruption of the thiamine treatment and recovered after reinitiating. Although unrelated, all patients came from the province Al Hoceima in Northern Morocco. Based on the recombination events the mutation was estimated to have occurred 1250-1750 years ago. Our data shows that SLC19A3 is a new candidate for mutation screening in patients with Leigh syndrome, who might benefit from high doses of thiamine and/or biotin. Especially, Moroccan patients with Leigh syndrome should be tested for the c.20C>A founder mutation in SLC19A3. ? 2013 The Author (2013). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved.
机译:Leigh综合征是一种早期发作,通常由线粒体或核DNA突变引起的致命性进行性神经退行性疾病。迄今为止,已经报道了超过35个基因的突变导致了Leigh综合征,表明该疾病具有极端的遗传异质性,但仍仅能解释部分病例。整个外显子组测序的可能性不仅使已知候选基因的突变检测成为可能,而且还使小家族和孤立病例中与李氏综合征相关的新基因得以鉴定。外显子组测序与纯合性作图相结合,可鉴定出摩洛哥儿童家族中致命致命的Leigh综合征的遗传缺陷,以及大脑中特定的磁共振成像异常。我们在硫胺素转运蛋白SLC19A3中检测到纯合的无意义突变(c.20C> A; p.Ser7Ter)。体内野生型SLC19A3的过表达显示硫胺素摄取增加,而突变型SLC19A3的过表达则没有,表明该突变导致蛋白质缺失或功能缺失。使用常规的Sanger测序对另外17名Leigh综合征患者进行SLC19A3突变筛查。两名来自摩洛哥的亲属和近亲的两名无关患者,对于同一p.Ser7Ter突变是纯合的。这些患者中有一个显示出与第一个家庭患者相同的MRI异常。令人惊讶的是,接受硫胺素治疗的患者的预期寿命有所改善。第三家庭的一名患者因硫胺素治疗中断而恶化,并在重新开始治疗后康复。尽管没有关系,但所有患者均来自摩洛哥北部的Al Hoceima省。基于重组事件,该突变估计发生在1250-1750年前。我们的数据表明,SLC19A3是Leigh综合征患者中可能进行突变筛查的新候选人,他们可能会从高剂量的硫胺素和/或生物素中受益。尤其是,应该对摩洛哥患有Leigh综合征的患者进行SLC19A3中c.20C> A创始人突变的检测。 ? 2013作者(2013)。牛津大学出版社代表脑担保人发行。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号